[AsCNP_P5] Poster Session 5
Bipolar Disorders 2

Sat. Oct 12, 2019 4:40 PM - 6:10 PM Poster Hall (Multi-purpose Hall)

Chair: ‌Shang-ying TSAI (Department of Psychiatry, Taipei Medical University and Hospital, Taiwan)

+Add all to schedule

4:40 PM - 4:45 PM

[AsCNP-P5-1] Risk and Coaggregation of Major Psychiatric Disorders among First-Degree Relatives of Patients with Bipolar Disorder: A Nationwide Population-Based Study

^○MuHong CHEN^{1, 2}, Ya-Mei BAI^{1, 2}, Tung-Ping SU^{1, 2} (1. Department of Psychiatry, Taipei Veterans General Hospital, 2. Division of Psychiatry, School of Medicine, National Yang-Ming University, Taipei, Taiwan)

Cancelled

4:45 PM - 4:50 PM

[AsCNP-P5-2] Psychometric properties of the Clinically Useful Depression Outcome Scale supplemented with questions for the DSM-5 Mixed subtype (CUDOS-M) in Chinese patients with mood disorders

^○Yanli DU¹, Jianbo HU², Tingting HUANG¹, Jianbo LAI², Weihua ZHANG¹, Chao LI¹, Zhongya XU³, Hetong ZHOU², Shaohua HU², Liemin RUAN⁴ (1. Zhejiang University School of Medicine, Hangzhou, China, 2. Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 3. Department of Psychiatry, Jiaxing Kangci Hospital, Jiaxing, China, 4. Department of Psychosomatics, Ningbo First Hospital, Ningbo, China)

[AsCNP-P5-3] Withdraw

[AsCNP-P5-4] Withdraw

Cancelled

4:50 PM - 4:55 PM

[AsCNP-P5-5] Reduced plasma orexin-A levels in patients with bipolar disorder

^○Shoko TSUCHIMINE¹, Kotaro HATTORI¹, Miho OTA¹, Shinsuke HIDESE¹, Toshiya TERAISHI¹, Daimei SASAYAMA¹, Hiroaki HORI¹, Takamasa NODA², Sumiko YOSHIDA², Fuyuko YOSHIDA¹, Hiroshi KUNUGI¹ (1. Department of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 2. Department of Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry)

4:55 PM - 5:00 PM

[AsCNP-P5-6] No evidence for association between mood stabilizer and plasma FGF21 level in bipolar disorder

^○Sayuri ISHIWATA¹, Hisayoshi TAKAI², Favour OMILEKE¹, Kotaro HATTORI^{1, 3}, Fuyuko YOSHIDA¹, Shinsuke HIDESE¹, Junko MATSUO¹, Ikki ISHIDA¹, Moeko HIRAISHI¹, Hiroshi KUNUGI¹ (1. Deparmtent of Mental Disorder Research, National Center of Neurology and Psychiatry, Tokyo, Japan, 2. Kawasaki City Institute for Public Health, Kawasaki, Japan, 3. Medical Genom Center, National Center of Neurology and Psychiatry, Tokyo, Japan)